Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA.

Fujita H, Kitawaki T, Sato T, Maeda T, Kamihira S, Takaori-Kondo A, Kadowaki N.

Eur J Immunol. 2013 Jan;43(1):93-103. doi: 10.1002/eji.201242699. Epub 2012 Dec 6.

2.

Dasatinib: an anti-tumour agent via Src inhibition.

Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V.

Curr Drug Targets. 2011 Apr;12(4):563-78. Review.

PMID:
21226671
3.

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

Montero JC, Seoane S, OcaƱa A, Pandiella A.

Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13. Review.

4.

Dasatinib in solid tumors.

Kim LC, Rix U, Haura EB.

Expert Opin Investig Drugs. 2010 Mar;19(3):415-25. doi: 10.1517/13543781003592097. Review.

PMID:
20113198
5.

Plasmacytoid dendritic cell role in cutaneous malignancies.

Saadeh D, Kurban M, Abbas O.

J Dermatol Sci. 2016 Jul;83(1):3-9. doi: 10.1016/j.jdermsci.2016.05.008. Epub 2016 May 13. Review.

PMID:
27236509
6.

Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Ahluwalia MS, de Groot J, Liu WM, Gladson CL.

Cancer Lett. 2010 Dec 8;298(2):139-49. doi: 10.1016/j.canlet.2010.08.014. Review.

7.

Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases.

Saadeh D, Kurban M, Abbas O.

Exp Dermatol. 2016 Jun;25(6):415-21. doi: 10.1111/exd.12957. Epub 2016 Apr 12. Review.

PMID:
26837058
8.

Plasmacytoid dendritic cells: biomarkers or potential therapeutic targets in atherosclerosis?

Grassia G, MacRitchie N, Platt AM, Brewer JM, Garside P, Maffia P.

Pharmacol Ther. 2013 Feb;137(2):172-82. doi: 10.1016/j.pharmthera.2012.10.001. Epub 2012 Oct 8. Review.

PMID:
23059425
9.

Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides.

Bayik D, Gursel I, Klinman DM.

Pharmacol Res. 2016 Mar;105:216-25. doi: 10.1016/j.phrs.2015.11.010. Epub 2016 Jan 15. Review.

PMID:
26779666
10.

Do Type I Interferons Link Systemic Autoimmunities and Metabolic Syndrome in a Pathogenetic Continuum?

Ganguly D.

Trends Immunol. 2017 Aug 17. pii: S1471-4906(17)30126-6. doi: 10.1016/j.it.2017.07.001. [Epub ahead of print] Review.

PMID:
28826817

Supplemental Content

Support Center